Marksans Pharma

261.42
+1.18
(0.45%)
Market Cap
11,849.90 Cr
EPS
6.92
PE Ratio
31.14
Dividend Yield
0.31 %
Industry
Healthcare
52 Week High
358.70
52 Week Low
130.00
PB Ratio
4.80
Debt to Equity
0.10
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Marksans Pharma: UK Regulator Approves Subsidiary's Diabetes Medication1 day ago
Marksans Pharma's subsidiary Relonchem Ltd received marketing authorization from UK MHRA for Metformin Hydrochloride oral solution (500 mg/5 ml) to treat high blood sugar levels. This approval expands Marksans Pharma's presence in the UK anti-diabetic market.
positive
Marksans Pharma's UK Unit Receives Marketing Authorization for Metformin Solution1 day ago
Relonchem Limited, a UK-based unit of Marksans Pharma, has received marketing authorization for Metformin Hydrochloride 500 mg/5ml Oral Solution. This approval allows the company to market and sell this specific formulation of the diabetes medication in the UK.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,677.60
#1 4,02,512.40
35.10
#1 49,887.20
12.06
#1 9,648
-18.99
42.28
6,612.00
1,75,527.80
80.12
8,184.00
0.89
1,600
23.05
63.47
1,465.70
1,18,372.10
22.44
26,520.70
14.17
4,155
30.28
44.20
3,174.70
1,07,446.30
55.71
10,785.70
11.59
1,656
10.91
44.55
1,251.20
1,04,407.10
#1 18.47
28,905.40
12.36
5,578
21.14
67.52
2,467.70
1,01,812.00
51.37
10,615.60
19.57
1,942
-10.91
48.86
930.00
93,579.80
20.04
19,831.50
13.82
3,831
-0.19
63.14
1,957.70
89,377.00
27.25
20,141.50
#1 19.94
1,936
#1 112.49
43.05
1,147.80
66,664.40
19.29
29,559.20
17.55
3,169
-0.50
43.00
30,455.00
64,714.70
45.75
6,097.20
10.80
1,201
27.83
50.48
Forecast
Actual
Growth Rate
Revenue Growth
16.55 %
Net Income Growth
18.70 %
Cash Flow Change
-2.95 %
ROE
0.47 %
ROCE
1.17 %
EBITDA Margin (Avg.)
9.54 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
171
210
256
217
210
187
187
215
192
221
274
219
199
239
268
249
257
247
264
288
335
331
360
355
336
355
370
375
433
450
467
498
497
510
550
591
577
606
653
710
725
Expenses
132
160
204
187
206
173
180
188
177
192
249
190
195
200
232
212
232
213
223
240
266
261
273
267
235
272
301
305
354
361
372
403
376
398
417
453
450
462
506
543
583
EBITDA
39
50
51
31
4
14
7
27
15
29
25
29
4
39
36
36
25
35
41
47
69
70
87
88
101
83
69
70
79
89
94
94
121
112
133
138
126
143
147
167
142
Operating Profit %
23 %
24 %
20 %
14 %
2 %
7 %
0 %
12 %
4 %
13 %
9 %
13 %
2 %
15 %
14 %
15 %
6 %
13 %
13 %
16 %
21 %
21 %
23 %
25 %
29 %
22 %
17 %
16 %
15 %
17 %
18 %
16 %
23 %
20 %
21 %
23 %
20 %
22 %
21 %
20 %
18 %
Depreciation
4
5
6
10
8
5
6
12
8
7
7
6
6
6
6
5
6
5
5
7
10
7
19
9
1
8
7
9
21
11
14
13
14
14
18
22
21
20
20
21
23
Interest
1
3
3
2
2
1
1
2
2
2
3
2
4
2
3
2
2
2
3
2
2
2
2
2
3
1
2
1
5
2
3
2
2
2
2
3
5
3
3
3
3
Profit Before Tax
36
45
43
19
0
7
-0
13
-1
20
15
21
-6
30
28
30
17
28
34
38
58
61
66
78
97
75
60
60
53
76
78
79
104
97
114
113
100
120
125
143
116
Tax
10
13
7
-0
4
2
-1
2
2
5
4
4
1
6
7
4
7
5
8
9
15
12
15
19
18
12
14
12
23
16
18
17
22
26
30
30
23
31
27
38
25
Net Profit
26
32
36
19
-4
5
1
12
-3
14
10
18
-7
25
21
25
10
23
26
30
43
49
51
59
80
63
46
48
30
60
60
62
83
70
84
83
78
89
98
105
91
EPS in ₹
0.61
0.77
0.85
0.44
-0.14
0.11
0.02
0.24
0.00
0.33
0.23
0.41
-0.17
0.58
0.48
0.60
0.21
0.52
0.63
0.71
1.00
1.20
1.21
1.42
1.93
1.51
1.11
1.20
0.69
1.46
1.52
1.56
1.97
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2.00

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
676
722
752
729
804
903
1,229
1,640
2,190
2,681
Fixed Assets
166
270
267
279
270
303
309
428
486
776
Current Assets
509
440
484
449
531
594
903
1,201
1,675
1,863
Capital Work in Progress
0
0
0
0
0
0
12
3
10
9
Investments
0
0
0
0
0
0
0
0
1
27
Other Assets
510
453
485
450
534
600
908
1,209
1,694
1,869
Total Liabilities
676
722
752
729
804
903
1,229
1,640
2,190
2,681
Current Liabilities
286
259
296
233
233
229
299
356
341
390
Non Current Liabilities
2
0
16
16
18
25
25
61
84
205
Total Equity
388
463
440
480
553
649
905
1,223
1,765
2,086
Reserve & Surplus
326
401
393
430
502
595
846
1,068
1,700
2,020
Share Capital
53
53
41
41
41
41
41
41
45
45

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
138
-150
-10
15
-7
60
119
94
176
21
Investing Activities
-33
-123
-21
-39
-14
-60
-45
-84
-259
-141
Operating Activities
155
31
14
50
27
233
179
99
237
230
Financing Activities
17
-58
-4
3
-21
-114
-15
80
198
-69

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Jan 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
48.25 %
48.25 %
48.25 %
48.25 %
48.25 %
48.25 %
48.60 %
49.00 %
43.80 %
43.85 %
43.85 %
43.85 %
43.85 %
43.85 %
43.87 %
43.87 %
43.87 %
43.87 %
FIIs
1.00 %
0.59 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.88 %
10.88 %
10.88 %
10.88 %
10.88 %
15.57 %
18.60 %
21.31 %
21.96 %
22.20 %
DIIs
0.09 %
0.34 %
0.34 %
0.34 %
0.46 %
0.95 %
0.95 %
0.96 %
0.87 %
1.46 %
3.65 %
3.15 %
3.82 %
5.17 %
3.75 %
4.10 %
4.30 %
4.56 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.15 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
41.50 %
41.71 %
42.41 %
42.47 %
41.36 %
40.77 %
39.76 %
39.69 %
35.19 %
34.42 %
32.36 %
32.12 %
30.80 %
30.91 %
29.47 %
26.77 %
26.24 %
25.77 %
Others
9.15 %
9.11 %
9.00 %
8.94 %
9.78 %
10.04 %
10.69 %
10.34 %
9.25 %
9.39 %
9.25 %
10.00 %
10.64 %
4.49 %
4.31 %
3.95 %
3.63 %
3.59 %
No of Share Holders
0
1,35,271
1,88,888
2,01,451
2,14,998
2,20,090
2,21,359
2,17,743
2,13,123
1,98,382
1,88,447
2,07,937
2,37,377
2,54,699
2,35,500
2,48,845
2,59,813
2,57,273

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.05 0.05 0.05 0.1 0.25 0.25 0.5 0.6 0.00
Dividend Yield (%) 0.00 0.16 0.2 0.36 0.2 0.55 0.34 0.33 0.27 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
19 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
19 May 2025 225.54 241.40
11 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Feb 2025 259.15 267.40
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 266.10 288.60
24 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
24 Sept 2024 209.01 314.54
17 Sept 2024 DIVIDEND Dividend
₹ 0.60 /share
17 Sept 2024 169.55 293.85
07 Jun 2023 DIVIDEND Dividend
₹ 0.50 /share
07 Jun 2023 75.73 89.51
23 Aug 2022 DIVIDEND Dividend
₹ 0.25 /share
19 Aug 2022 46.70 50.80
17 Sept 2021 DIVIDEND Dividend
₹ 0.25 /share
15 Sept 2021 73.95 71.05

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Compliances-Reg.24(A)-Annual Secretarial Compliance2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome5 days ago
Newspaper Advertisement Of Financial Results For The Quarter And Year Ended March 31 20259 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome10 days ago
Audited Results For The Year Ended March 31 2025May 19, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2025
Board Meeting Outcome for Board Meeting Outcome For Consideration And Approval Of Audited Results For The Year Ended March 31 2025May 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 09, 2025
Board Meeting Intimation for To Consider And Approve Audited Financial Results (Both Standalone And Consolidated) For The Quarter And Year Ended March 31 2025 And To Consider Recommendation Of Dividend On Equity Shares For The Financial Year 2024-25 If AnMay 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 28, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Announcement under Regulation 30 (LODR)-CessationMar 31, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 19, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMar 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 25, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 25, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Feb 11, 2025
Integrated Filing (Financial)Feb 11, 2025
Statement Of Deviation For The Quarter Ended December 31 2024Feb 11, 2025
Financial Results For Quarter And Nine Months Ended December 31 2024Feb 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 11, 2025
Board Meeting Outcome for For The Quarter And Nine-Month Period Ended December 31 2024Feb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 30, 2025
Board Meeting Intimation for To Consider And Approve Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Closure of Trading WindowDec 30, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 11, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 25, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 22, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 13, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2024
Statement Of Deviation Or Variation For The Quarter Ended September 30, 2024Nov 12, 2024
Financial Results For Quarter And Half Year Ended September 30, 2024Nov 12, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 12, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2024
Board Meeting Outcome for Outcome Of Board MeetingNov 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 05, 2024
Announcement under Regulation 30 (LODR)-Credit RatingOct 28, 2024

Technical Indicators

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
TRUSTMF Small Cap Fund Direct-Growth
0
0.00%
-1.21%
-1.06%
Apr 2025
Kotak Healthcare Fund Direct - Growth
440000
2.33%
0.98%
0.98%
Apr 2025
Old Bridge Focused Equity Fund Direct - Growth
1857079
2.78%
-0.33%
-0.52%
Apr 2025
UTI Small Cap Fund Direct - Growth
2103104
1.09%
-0.30%
-0.29%
Apr 2025
Kotak Special Opportunities Fund Direct-Growth
2527836
2.78%
-0.14%
0.00%
Apr 2025
Kotak MNC Fund Direct-Growth
2000000
2.03%
-0.10%
0.47%
Apr 2025
UTI Large & Mid Cap Fund Direct-Growth
1072411
0.54%
-0.04%
-0.04%
Apr 2025
UTI Aggressive Hybrid Fund Direct Fund-Growth
1508646
0.54%
-0.03%
-0.01%
Apr 2025
Bandhan BSE Healthcare Index Fund Direct-Growth
2904
0.35%
-0.02%
-0.02%
Apr 2025
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth
602337
0.67%
-0.02%
-0.04%
Apr 2025
UTI Healthcare Fund Direct-Growth
687969
1.45%
-0.01%
0.12%
Apr 2025
Bandhan Small Cap Fund Direct-Growth
1405689
0.30%
0.01%
0.00%
Apr 2025
UTI Retirement Fund Direct
537666
0.25%
-0.01%
0.00%
Apr 2025
Angel One Nifty Total Market Index Fund Direct - Growth
365
0.02%
0.00%
0.02%
Apr 2025
Groww Nifty Total Market Index Fund Direct - Growth
3120
0.02%
0.00%
0.00%
Apr 2025
TRUSTMF Flexi Cap Fund Direct - Growth
0
0.00%
0.00%
0.00%
Apr 2025
Motilal Oswal Quant Fund Direct-Growth
0
0.00%
0.00%
0.00%
Apr 2025
Mirae Asset Nifty Total Market Index Fund Direct-Growth
425
0.02%
0.00%
0.00%
Apr 2025
Bandhan Nifty Total Market Index Fund Direct-Growth
412
0.02%
0.00%
0.00%
Apr 2025
Samco Active Momentum Fund Direct - Growth
0
0.00%
0.00%
-0.66%
Apr 2025
Samco Multi Cap Fund Direct-Growth
0
0.00%
0.00%
0.00%
Apr 2025
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0
0.00%
0.00%
0.00%
Apr 2025